The use of everolimus in pediatric kidney transplantation

Pediatric Transplantation

Volumn 18, Issue 4, 2014, Pages 323-324

  Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; EVEROLIMUS; PREDNISONE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ACUTE GRAFT REJECTION; CHRONIC GRAFT REJECTION; EDITORIAL; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; PEDIATRIC SURGERY; PROPHYLAXIS; ANALOGS AND DERIVATIVES; FEMALE; GRAFT REJECTION; MALE;

CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; SIROLIMUS;

EID: 84900028225     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12268     Document Type: Editorial

References (11)

1. Ferraresso M, Belingheri M, Ginevri F, et al. Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients. Pediatr Transplant 2014: 18: 350-356.
2. Cibrik D, Silva HT, Vathsala A, et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013: 95: 933-942.
3. Pape L, Offner G, Kreuzer M, et al. De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 2010: 10: 2349-2354.
4. Pape L, Lehner F, Blume C, Ahlenstiel T,. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Transplantation 2011: 92: 658-662.
5. Ganschow R, Pape L, Sturm E, et al. Growing experience with mTOR inhibitors in pediatric solid organ transplantation. Pediatr Transplant 2013: 17: 694-706.
6. Grushkin C, Mahan JD, Mange KC, Hexham JM, Ettenger R,; for the Everolimus Pediatric Study Group. De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: A prospective, multicenter, 12-month study. Pediatr Transplant 2013: 17: 237-243.
7. Kanzelmeyer NK, Ahlenstiel T, Drube J, et al. Protocol biopsy-driven interventions after pediatric renal transplantation. Pediatr Transplant 2010: 14: 1012-1018.
8. Ettenger R, Hoyer PF, Grimm P, et al. Multicenter trial of everolimus in pediatric renal transplant recipients: Results at three year. Pediatr Transplant 2008: 12: 456-463.
9. Tönshoff B, Pape L, Ettenger R,et al. Early conversion of calcineurin inhibitor to everolimus in de novo paediatric renal transplant recipients and its impact on efficacy and renal function; design of an open-label, randomised, multi-centre study. 24th International Congress of the Transplantation Society, July 15-19, 2012 THU.PO39.035.
10. Kranz B, Wingen AM, Vester U, König J, Hoyer PF,. Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation. Pediatr Nephrol 2013: 28: 1293-1298.
11. Billing H, Burmeister G, Plotnicki L, et al. Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients. Transpl Int 2013: 26: 903-909.